On October 14, 2021, under Topic 1, the committee will meet in open session to discuss the EUA of the Moderna COVID-19 mRNA vaccine for the administration of a booster dose, following completion of the primary series, to individuals 18 years of age and older. On October 15, 2021, under Topic II, the committee will meet in open session to discuss the EUA of the Janssen Biotech Inc. COVID-19 vaccine for the administration of a booster dose, to individuals 18 years of age and older.